Amicus Therapeutics logo

Amicus TherapeuticsNASDAQ: FOLD

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

31 May 2007

Next earnings report:

08 November 2024

Last dividends:

N/A

Next dividends:

N/A
$3.41 B
-22%vs. 3y high
86%vs. sector
-vs. 3y high
-vs. sector
-30%vs. 3y high
98%vs. sector
-36%vs. 3y high
68%vs. sector

Price

regular market | 1 min ago
$11.49+$0.04(+0.39%)

Dividend

No data over the past 3 years
$126.67 M$135.33 M
$126.67 M-$15.70 M

Analysts recommendations

Institutional Ownership

FOLD Latest News

Wall Street Analysts Predict a 51.09% Upside in Amicus Therapeutics (FOLD): Here's What You Should Know
zacks.com04 November 2024 Sentiment: -

The consensus price target hints at a 51.1% upside potential for Amicus Therapeutics (FOLD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Amicus Therapeutics to Announce Third Quarter 2024 Financial Results on November 6, 2024
globenewswire.com28 October 2024 Sentiment: POSITIVE

PRINCETON, N.J., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Wednesday, November 6, 2024, at 8:30 a.m. ET to discuss financial results for the third quarter ended September 30, 2024.

Why Amicus Therapeutics (FOLD) is a Top Momentum Stock for the Long-Term
zacks.com21 October 2024 Sentiment: POSITIVE

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Amicus: Teva Settlement Clears Revenue Path Forward For Galafold
seekingalpha.com18 October 2024 Sentiment: POSITIVE

Amicus Therapeutics settled litigation with Teva, preventing a generic version of Galafold for Fabry Disease until 2037, ensuring revenue growth. Pombiliti + Opfolda approved for late-onset Pompe Disease, with potential label expansion to children and infants with successful studies, boosting market opportunity. Galafold sales grew 17% YoY to $110.8 million in Q2 of 2024, with full-year 2024 revenue growth guidance raised to 14%-18%.

FOLD Stock Rises on Settling Galafold Patent Dispute With Teva
zacks.com18 October 2024 Sentiment: POSITIVE

Amicus stock gains on reaching a licensing deal with Teva, which ends their Galafold patent lawsuit.

Amicus Therapeutics (FOLD) Stock Jumps 14.0%: Will It Continue to Soar?
zacks.com18 October 2024 Sentiment: POSITIVE

Amicus Therapeutics (FOLD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Amicus Therapeutics Announces Settlement of Galafold® (migalastat) Patent Litigation with Teva
globenewswire.com17 October 2024 Sentiment: POSITIVE

Company Grants Teva a License to Market Generic Galafold® Beginning in January 2037 Company Grants Teva a License to Market Generic Galafold® Beginning in January 2037

Amicus Therapeutics Announces Participation at the World Muscle Society Annual Congress 2024
globenewswire.com04 October 2024 Sentiment: POSITIVE

PRINCETON, N.J., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced that three posters highlighting its development program for Pompe disease will be included at the 29th Annual Congress of the World Muscle Society being held October 8-12, 2024 in Prague, Czechia.

'Boring' Amicus Therapeutics Is Making Progress
seekingalpha.com29 September 2024 Sentiment: POSITIVE

Amicus Therapeutics is making steady progress towards promised profitability, driven by the continued growth of Galafold and the launch of Pombiliti+Opfolda. The "beat-and-raise" guidance profile is missing this year and could partially explain the lack of the year-to-date share price momentum. Pombiliti+Opfolda's launch is progressing well, with patients switching from both Nexviazyme and Lumizyme.

Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2024
globenewswire.com03 September 2024 Sentiment: POSITIVE

PRINCETON, N.J., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in September.

  • 1(current)
  • 2

What type of business is Amicus Therapeutics?

Amicus Therapeutics, Inc. is a global biotechnology company dedicated to the discovery, development, and delivery of medicines for the treatment of rare diseases. Amicus Therapeutics, Inc. was registered in 2002, with its headquarters located in Philadelphia, Pennsylvania. The company's main product is Galafold, the first approved oral precision medicine for people living with Fabry disease and having genetically amenable variants. The drug is approved under the trade name Galafold in the United States, European Union, United Kingdom, and Japan, with several additional approvals and applications under review in multiple regions worldwide.

What sector is Amicus Therapeutics in?

Amicus Therapeutics is in the Healthcare sector

What industry is Amicus Therapeutics in?

Amicus Therapeutics is in the Biotechnology industry

What country is Amicus Therapeutics from?

Amicus Therapeutics is headquartered in United States

When did Amicus Therapeutics go public?

Amicus Therapeutics initial public offering (IPO) was on 31 May 2007

What is Amicus Therapeutics website?

https://amicusrx.com

Is Amicus Therapeutics in the S&P 500?

No, Amicus Therapeutics is not included in the S&P 500 index

Is Amicus Therapeutics in the NASDAQ 100?

No, Amicus Therapeutics is not included in the NASDAQ 100 index

Is Amicus Therapeutics in the Dow Jones?

No, Amicus Therapeutics is not included in the Dow Jones index

When was Amicus Therapeutics the previous earnings report?

No data

When does Amicus Therapeutics earnings report?

The next expected earnings date for Amicus Therapeutics is 08 November 2024